174 related articles for article (PubMed ID: 9207379)
21. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.
Savarino A; Lucia MB; Rastrelli E; Rutella S; Golotta C; Morra E; Tamburrini E; Perno CF; Boelaert JR; Sperber K; Cauda R
J Acquir Immune Defic Syndr; 2004 Mar; 35(3):223-32. PubMed ID: 15076236
[TBL] [Abstract][Full Text] [Related]
22. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
23. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
[TBL] [Abstract][Full Text] [Related]
24. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
Inaba T; Fischer NE; Riddick DS; Stewart DJ; Hidaka T
Toxicol Lett; 1997 Dec; 93(2-3):215-9. PubMed ID: 9486958
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.
Rouquayrol M; Gaucher B; Greiner J; Aubertin AM; Vierling P; Guedj R
Carbohydr Res; 2001 Nov; 336(3):161-80. PubMed ID: 11705466
[TBL] [Abstract][Full Text] [Related]
26. Antimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques.
Li Y; Qin L; Peng N; Liu G; Zhao S; He Z; Chen X
Antimicrob Agents Chemother; 2011 Jun; 55(6):3039-42. PubMed ID: 21486958
[TBL] [Abstract][Full Text] [Related]
27. Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.
Dupuis ML; Tombesi M; Sabatini M; Cianfriglia M
Chemotherapy; 2003 May; 49(1-2):8-16. PubMed ID: 12714803
[TBL] [Abstract][Full Text] [Related]
28. Invirase resistance/cross-resistance data released.
AIDS Patient Care STDS; 1996 Jun; 10(3):185. PubMed ID: 11361626
[No Abstract] [Full Text] [Related]
29. Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants.
Zhu Q; Yu Z; Kabashima T; Yin S; Dragusha S; El-Mahdy AF; Ejupi V; Shibata T; Kai M
Sci Rep; 2015 May; 5():10323. PubMed ID: 25988960
[TBL] [Abstract][Full Text] [Related]
30. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
Mammano F; Trouplin V; Zennou V; Clavel F
J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
[TBL] [Abstract][Full Text] [Related]
31. In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors.
Lazdins JK; Mestan J; Goutte G; Walker MR; Bold G; Capraro HG; Klimkait T
J Infect Dis; 1997 May; 175(5):1063-70. PubMed ID: 9129067
[TBL] [Abstract][Full Text] [Related]
32. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
[TBL] [Abstract][Full Text] [Related]
33. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.
Martinez-Picado J; Savara AV; Shi L; Sutton L; D'Aquila RT
Virology; 2000 Sep; 275(2):318-22. PubMed ID: 10998332
[TBL] [Abstract][Full Text] [Related]
34. Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.
Walzer PD; Ashbaugh A; Collins M; Cushion MT
J Infect Dis; 2001 Nov; 184(10):1355-7. PubMed ID: 11679930
[TBL] [Abstract][Full Text] [Related]
35. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors.
Zhang XQ; Schooley RT; Gerber JG
J Infect Dis; 1999 Dec; 180(6):1833-7. PubMed ID: 10558938
[TBL] [Abstract][Full Text] [Related]
36. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
Eagling VA; Back DJ; Barry MG
Br J Clin Pharmacol; 1997 Aug; 44(2):190-4. PubMed ID: 9278209
[TBL] [Abstract][Full Text] [Related]
37. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Dupuis ML; Flego M; Molinari A; Cianfriglia M
HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
[TBL] [Abstract][Full Text] [Related]
38. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.
Martinez-Picado J; Savara AV; Sutton L; D'Aquila RT
J Virol; 1999 May; 73(5):3744-52. PubMed ID: 10196268
[TBL] [Abstract][Full Text] [Related]
39. Antileishmanial activity of HIV protease inhibitors.
Savoia D; Allice T; Tovo PA
Int J Antimicrob Agents; 2005 Jul; 26(1):92-4. PubMed ID: 15955671
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
